Cervical Cancer
Conditions
Interventions
Experimental group:Give fluorescent imaging agents TMTP1-ICG
control group:Give fluorescent imaging agents ICG
Sponsors
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Fluorescence laparoscopic inclusion criteria: (1) Married female patients over 18 years of age, who have been or are not required; (2) cervical biopsy was diagnosed as cervical squamous cell carcinoma; (3) clinical stage in IA1-IIB period; (4) to meet the indications for laparoscopic surgery; (5) meet ethical requirements, patients and / or family members to sign informed consent. Fluorescence colposcope incorporation criteria: (1) cervical suspicious lesions, intended to colposcopy biopsy female patients; (2) meet ethical requirements, patients and / or family members to sign informed consent.;Inclusion criteria: Fluorescence laparoscopic inclusion criteria: (1) Married female patients over 18 years of age, who have been or are not required; (2) cervical biopsy was diagnosed as cervical squamous cell carcinoma; (3) clinical stage in IA1-IIB period; (4) to meet the indications for laparoscopic surgery; (5) meet ethical requirements, patients and / or family members to sign informed consent. Fluorescence colposcope incorporation criteria: (1) cervical suspicious lesions, intended to colposcopy biopsy female patients; (2) meet ethical requirements, patients and / or family members to sign informed consent.;Inclusion criteria: Fluorescence laparoscopic inclusion criteria: (1) Married female patients over 18 years of age, who have been or are not required; (2) cervical biopsy was diagnosed as cervical squamous cell carcinoma; (3) clinical stage in IA1-IIB period; (4) to meet the indications for laparoscopic surgery; (5) meet ethical requirements, patients and / or family members to sign informed consent. Fluorescence colposcope incorporation criteria: (1) cervical suspicious lesions, intended to colposcopy biopsy female patients; (2) meet ethical requirements, patients and / or family members to sign informed consent.;Inclusion criteria: Fluorescence laparoscopic inclusion criteria: (1) Married female patients over 18 years of age, who have been or are not required; (2) cervical biopsy was diagnosed as cervical squamous cell carcinoma; (3) clinical stage in IA1-IIB period; (4) to meet the indications for laparoscopic surgery; (5) meet ethical requirements, patients and / or family members to sign informed consent. Fluorescence colposcope incorporation criteria: (1) cervical suspicious lesions, intended to colposcopy biopsy female patients; (2) meet ethical requirements, patients and / or family members to sign informed consent.;Inclusion criteria: Fluorescence laparoscopic inclusion criteria: (1) Married female patients over 18 years of age, who have been or are not required; (2) cervical biopsy was diagnosed as cervical squamous cell carcinoma; (3) clinical stage in IA1-IIB period; (4) to meet the indications for laparoscopic surgery; (5) meet ethical requirements, patients and / or family members to sign informed consent. Fluorescence colposcope incorporation criteria: (1) cervical suspicious lesions, intended to colposcopy biopsy female patients; (2) meet ethical requirements, patients and / or family members to sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Pregnancy, lactating women; (2) has been diagnosed bacterial vaginitis, fungal vaginitis, a variety of sexually transmitted diseases are positive; (3) known drugs or alcohol dependent or suspected to be allergic to the active or inactive ingredients of the study drug; (4) 3 months before the trial participated in other drug clinical trials; (5) patients with cardiac insufficiency; (6) patients with liver function and renal insufficiency; (7) patients with severe complications of hypertension; (8) patients who may be life-threatening in the study.;Exclusion criteria: (1) Pregnancy, lactating women; (2) has been diagnosed bacterial vaginitis, fungal vaginitis, a variety of sexually transmitted diseases are positive; (3) known drugs or alcohol dependent or suspected to be allergic to the active or inactive ingredients of the study drug; (4) 3 months before the trial participated in other drug clinical trials; (5) patients with cardiac insufficiency; (6) patients with liver function and renal insufficiency; (7) patients with severe complications of hypertension; (8) patients who may be life-threatening in the study.;Exclusion criteria: (1) Pregnancy, lactating women; (2) has been diagnosed bacterial vaginitis, fungal vaginitis, a variety of sexually transmitted diseases are positive; (3) known drugs or alcohol dependent or suspected to be allergic to the active or inactive ingredients of the study drug; (4) 3 months before the trial participated in other drug clinical trials; (5) patients with cardiac insufficiency; (6) patients with liver function and renal insufficiency; (7) patients with severe complications of hypertension; (8) patients who may be life-threatening in the study.;Exclusion criteria: (1) Pregnancy, lactating women; (2) has been diagnosed bacterial vaginitis, fungal vaginitis, a variety of sexually transmitted diseases are positive; (3) known drugs or alcohol dependent or suspected to be allergic to the active or inactive ingredients of the study drug; (4) 3 months before the trial participated in other drug clinical trials; (5) patients with cardiac insufficiency; (6) patients with liver function and renal insufficiency; (7) patients with severe complications of hypertension; (8) patients who may be life-threatening in the study.;Exclusion criteria: (1) Pregnancy, lactating women; (2) has been diagnosed bacterial vaginitis, fungal vaginitis, a variety of sexually transmitted diseases are positive; (3) known drugs or alcohol dependent or suspected to be allergic to the active or inactive ingredients of the study drug; (4) 3 months before the trial participated in other drug clinical trials; (5) patients with cardiac insufficiency; (6) patients with liver function and renal insufficiency; (7) patients with severe complications of hypertension; (8) patients who may be life-threatening in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymph node fluorescence; | — |
Countries
China
Contacts
Public ContactDing Ma;Ding Ma;Ding Ma;Ding Ma;Ding Ma ;;;;
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology;Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology;Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology;Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Outcome results
None listed